Skip to content

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    12 to 45

Participation Criteria

Inclusion Criteria:

* Age 12 to 45 at screening
* Has a designated care/study partner who can reliably report on symptoms
* Has a diagnosis of Autism Spectrum Disorder (ASD)
* Has a body mass index (BMI) 18 through 34 kg/m², inclusive
* Full scale IQ (or equivalent) ≥55 score, with adequate verbal fluency, as determined by the Principal Investigator.
* Psychoactive medications and adjunctive therapies are stable for 4 weeks prior to screening
* Must be able to swallow study medication

Exclusion Criteria:

* Has Rett syndrome or Child Disintegrative Disorder
* Has participated in any other study and received any other investigational medication (other than COVID-19 vaccination) or device within 60 days prior to screening
* History of epilepsy without current adequate control, or any seizure in the 6 months preceding screening
* History of suicidal ideation or behavior in the past 12 months, or a positive response to C-SSRS questions 4 and/or 5
* Systolic blood pressure ≥140 mmHg (if adult) or \>135 mmHg (if adolescent), or diastolic blood pressure ≥90 (if adult) or \>85 mmHg (if adolescent), or a clinical history of uncontrolled or severe hypertension
* If female, is pregnant or lactating

Study Location

Holland Bloorview Kids Rehabilitation Hospital
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Danielle Baribeau, MD, PhD

416-425-6220
OCT Research ULC (dba Okanagan Clinical Trials)
OCT Research ULC (dba Okanagan Clinical Trials)
Kelowna, British Columbia
Canada

Contact Study Team

Primary Contact

Euguene Okorie, MD

250-862-8141
Lawson Health Research Institute/ London Health Sciences Centre
Lawson Health Research Institute/ London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

Primary Contact

Rob Nicolson, MD, FRCP (C)

519-685-8427
Study Sponsored By
MapLight Therapeutics
Participants Required
More Information
Study ID: NCT05081245